AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net product sales rose to $308.0 million from $264.6 million a year ago, but SG&A jumped to $160.3 million, holding operating income to $37.8 million.
Biggest Revenue Drivers
NUPLAZID$183.1M
Increase of $14.7 million due to growth in NUPLAZID unit sales in 2026 compared to 2025
DAYBUE products$124.8M
Increase of $28.7 million due to growth in DAYBUE unit sales and a higher average net selling price
Biggest Revenue Drivers
Total revenue: $308.0M
NUPLAZID$183.1M
Increase of $14.7 million due to growth in NUPLAZID unit sales in 2026 compared to 2025
DAYBUE products$124.8M
Increase of $28.7 million due to growth in DAYBUE unit sales and a higher average net selling price
Largest Expense Items
Selling, general and administrative$160.3M
Increased expenditures for DAYBUE products and NUPLAZID in the U.S., including recent expansion of the DAYBUE and NUPLAZID teams
Research and development$81.6M
Increased expenditures for remlifanserin and ACP-211, offset by reduced spend on studies ending in 2025
Cost of product sales$28.3M
Approximately 9% of net product sales versus 8% a year ago; relatively flat as a percentage
Margins: Cost of product sales was approximately 9% of net product sales versus 8% a year earlier, which the filing describes as relatively flat.
Watch Items from the Filing
Two products generate all revenue; substantially all sales are to customers in North America, concentrating commercial and geographic risk.
Operating expenses grew to $270.1 million from $232.2 million, outpacing revenue growth and limiting operating income to $37.8 million.
Company may be required to make milestone payments up to $3.6 billion in aggregate for pipeline candidates.
Securities class action heading to trial: mandatory settlement conference August 17, 2026; no amounts accrued beyond attorneys' fees, exposure unestimable.
CHMP adopted a positive opinion in June 2026 recommending EU marketing authorization for trofinetide (DAYBU) in Rett syndrome.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
1 transaction in ACAD reported by 1 member of Congress under the STOCK Act, most recent trade Jun 16, 2022. Reported transactions, not recommendations.
About ACADIA PHARMACEUTICALS INC (ACAD): stock profile, AI score and financials
ACADIA PHARMACEUTICALS INC (ACAD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACAD at 67.9/100 on a composite quality score built from its SEC filings, placing it at rank #336 of 2,925 stocks — the top 25% of the AI-ranked universe. ACAD scores in the top quartile across balance sheet strength (97.6), profitability (94.1). Areas of concern include institutional flow (32.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ACADIA PHARMACEUTICALS INC reports quarterly revenue of $308.0M, net income of $31.5M, an operating margin of 12.3%. Top institutional holders of ACAD by reported 13-F value include BAKER BROS. ADVISORS, BlackRock, STATE STREET, based on the most recent SEC filings. ACAD trades on the Nasdaq exchange and files with the SEC under CIK 1070494. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACAD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ACADIA PHARMACEUTICALS INC directly from SEC EDGAR.